Page last updated: 2024-12-05
2,3-dibromopropanol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2,3-dibromopropanol: metabolite of ''Tris''. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 7281 |
| CHEMBL ID | 1403428 |
| SCHEMBL ID | 288971 |
| MeSH ID | M0066304 |
Synonyms (59)
| Synonym |
|---|
| STL301889 |
| 96-13-9 |
| nci-c55436 |
| 1,2-dibromopropan-3-ol |
| brominex 257 |
| 2,3-dibromo-1-propanol |
| nsc6203 |
| 2,3-dibromopropanol |
| 2,3-dibromopropyl alcohol |
| 1-propanol,3-dibromo- |
| usaf do-42 |
| wln: q1ye1e |
| nsc-6203 |
| dibromopropanol |
| 1-propanol, 2,3-dibromo- |
| beta-dibromohydrin |
| glycerol 1,2-dibromohydrin |
| allyl alcohol dibromide |
| 2,3-dibromopropan-1-ol |
| NCGC00091310-01 |
| hsdb 2879 |
| brn 1719127 |
| dbp (flame retardant) |
| ccris 940 |
| nsc 6203 |
| einecs 202-480-9 |
| ai3-26304 |
| 2,3-dibromo-1-propanol, 98% |
| glycerol alpha,beta-dibromohydrin |
| alpha,beta-dibromohydrin |
| D0204 |
| MLS002415682 |
| smr001370876 |
| NCGC00091310-02 |
| AKOS009157161 |
| 2,3-dibromo-propan-1-ol |
| C19224 |
| HMS3039C16 |
| tox21_200709 |
| dtxcid801817 |
| cas-96-13-9 |
| dtxsid7021817 , |
| NCGC00258263-01 |
| c0ybw1oa2i , |
| unii-c0ybw1oa2i |
| FT-0609523 |
| 2,3-dibromopropan-1-ol [hsdb] |
| SCHEMBL288971 |
| CHEMBL1403428 |
| 1,2-dibromohydrin |
| .beta.-dibromohydrin |
| c3h6br2o |
| J-802049 |
| mfcd00004699 |
| A858706 |
| E76987 |
| Q26840749 |
| brominex 257; dbp; nsc 6203 |
| AMY25826 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nearly all dosed rats had malignant neoplasms at one or more sites, while only one control male and one control female had malignant neoplasms." | ( Toxicity and carcinogenicity of 2,3-dibromo-1-propanol in F344/N rats and B6C3F1 mice. Abdo, KM; Eustis, SL; Haseman, JK; Mackenzie, WF, 1995) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (10)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 17.7828 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.2198 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 55.2037 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.1975 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 100.0000 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 0.1836 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.41) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.88%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (94.12%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||